Previous 10 | Next 10 |
2023-08-31 12:35:49 ET More on psychedelic drugmakers Compass Pathways: Debt Deal Secured, Cash Runway Extended COMPASS Pathways plc ( CMPS ) Q2 2023 Earnings Call Transcript Mind Medicine Inc. ( MNMD ) Q2 2023 Earnings Call Transcript Psychedelic Sto...
2023-08-22 12:50:11 ET More on psychedelic drug companies Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets. COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down Psychedelic Stocks: Don't Bet On Just 1 Company Seelos:...
2023-08-09 08:45:56 ET Palm Beach, FL – August 9, 2023 – FinancialNewsMedia.com News Commentary – About 9.4% of the world population is aged 65 or above. Older people typically consume more medicines than the people in other age group thereby creating the de...
2023-08-09 08:32:37 ET Tigo Energy ( TYGO ) -37% reports record revenues and gross profit for second quarter 2023. Bruush Oral Care ( BRSH ) -29% . Fitell Corporation ( FTEL ) -26% . Veritone ( VERI ) -26% after Q2 earning release . ...
2023-08-08 13:46:38 ET Shares of psychiatric drug developer Bright Minds Biosciences ( NASDAQ: DRUG ) rallied as much as 100% Tuesday ahead of a schedule conference call with investors to discuss Phase 1 results for its lead drug candidate BMB-101. Bright Minds shares opened at ...
2023-08-08 12:46:20 ET Gainers: Infinity Pharmaceuticals ( INFI ) +56% . Bright Minds Biosciences ( DRUG ) +46% . Tilray Brands ( TLRY ) +31% . Paymentus Holdings (PAY) +33% . Gorilla Technology Group ( GRRR ) +28% . Cardiff Onco...
2023-08-08 10:21:19 ET Gainers: Bright Minds Biosciences ( DRUG ) +62% . Bionomics ( BNOX ) +24% . Novo Nordisk ( NVO ) +18% . Quanterix ( QTRX ) +17% . Tilray Brands ( TLRY ) +18% . Losers: Vistagen Therapeutics ( VTGN ...
-- BMB-101 is a highly selective and potent 5-HT 2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders -- qEEG study was conducted in healthy individuals in Cohort 4 of the Multiple Ascend...
-- BMB-101 is a highly selective and potent 5-HT 2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders -- BMB-101 demonstrated an excellent safety and tolerability profile in single ascendin...
Thinking about buying stock in Mind Medicine (MindMed), OPKO Health, Grange Resources, Hyzon Motors, or Bright Minds Biosciences? PR Newswire NEW YORK , July 14, 2023 InvestorsObserver issues critical PriceWatch Alerts for MNMD, OPK, GRR, HYZN, and DRUG. ...
News, Short Squeeze, Breakout and More Instantly...
Bright Minds Biosciences Inc. Company Name:
DRUG Stock Symbol:
NASDAQ Market:
Algoma Steel Group Inc. (ASTL) is expected to report for Q3 2024 CTS Corporation (CTS) is expected to report for Q4 2023 Xylem Inc. New (XYL) is expected to report $0.96 for Q4 2023 TIM S.A. American Depositary Shares (Each representing 5) (TIMB) is expected to report for Q4 2023 ...
Bright Minds Biosciences Inc. (DRUG) is expected to report for quarter end 2023-12-31
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD A decade after it was founded as a wholly-owned ...